GSK may divest Horlicks and nutrition products

27 March 2018 - Deborah Wilkes

Archived

GlaxoSmithKline is reviewing strategic options, including divestment, for Horlicks and its other consumer healthcare nutrition products. The company said the review would support funding of its proposed USD13.0 billion acquisition of Novartis' 36.5% stake in the consumer healthcare joint venture between the two companies.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: